1. Scrip
  2. >>Business

UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit

£240m Investment Committed

 
• By Vibha Ravi and Andrew McConaghie

After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?

Hands holding a compass against background of a map
Which Country Will Be Part Of Serum Institute's Global Ambitions Next? • Source: Alamy

UK is set to be the wind beneath Serum Institute of India Pvt. Ltd.’s global wings as the company sets up a sales office and commits to investing £240m in the country.

After Serum Institute CEO Adar Poonawalla recently revealed to The Times an intention to set up a manufacturing plant outside India, Downing Street listed Serum Institute’s investment among deals

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.